Patents Assigned to Educational Foundation Jichi Medical University
-
Publication number: 20180214467Abstract: An object of the present invention is to provide a GLP-1 secretagogue which is an incretin hormone-related drug relatively inexpensive, excellent in safety, and capable of promoting GLP-1 secretion without containing sucrose as an essential constituent. The object is achieved by a GLP-1 secretagogue characterized by containing D-psicose as an active ingredient.Type: ApplicationFiled: July 29, 2016Publication date: August 2, 2018Applicants: EDUCATIONAL FOUNDATION JICHI MEDICAL UNIVERSITY, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, Matsutani Chemical Industry Co., Ltd.Inventors: Toshihiko YADA, Yusaku IWASAKI, Hiroshi HARA, Tohru HIRA, Yuka KISHIMOTO, Machiko MINAMI
-
Patent number: 9333249Abstract: The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients.Type: GrantFiled: August 15, 2008Date of Patent: May 10, 2016Assignees: EDUCATIONAL FOUNDATION JICHI MEDICAL UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Shigeto Yoshida, Masanori Kawasaki, Makoto Matsumoto, Yoshio Ohba, Masahiro Saito, Yoshihiro Goto, Katsuya Inagaki, Masami Mizukoshi, Norimitsu Hariguchi, Kuniko Hirota
-
Patent number: 9327018Abstract: The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients.Type: GrantFiled: September 14, 2012Date of Patent: May 3, 2016Assignees: EDUCATIONAL FOUNDATION JICHI MEDICAL UNIVERSITY, OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Shigeto Yoshida, Masanori Kawasaki, Makoto Matsumoto, Yoshio Ohba, Masahiro Saito, Yoshihiro Goto, Katsuya Inagaki, Masami Mizukoshi, Norimitsu Hariguchi, Kuniko Hirota
-
Patent number: 9244079Abstract: [Problem] The present invention provides a novel pathological marker of angiitis which serves as an alternative to MPO-ANCAs. [Means for Solution] According to one embodiment of the present invention, a method for testing angiitis which includes a step of detecting an antibody specifically recognizing a moesin in a biological sample is provided. In addition, according to another embodiment of the present invention, a reagent for testing angiitis which contains a substance that detects an antibody specifically recognizing a moesin in a biological sample is provided.Type: GrantFiled: May 12, 2011Date of Patent: January 26, 2016Assignees: National University Corporation Chiba University, Educational Foundation Jichi Medical UniversityInventors: Kazuo Suzuki, Toshinori Nakayama, Hiroshi Nakajima, Tomokazu Nagao, Wako Yumura
-
Patent number: 9109259Abstract: Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1.Type: GrantFiled: June 22, 2011Date of Patent: August 18, 2015Assignees: Japanese Foundation for Cancer Research, Educational Foundation Jichi Medical UniversityInventors: Kengo Takeuchi, Yuichi Ishikawa, Hiroyuki Mano, Manabu Soda, Eirin Sai
-
Patent number: 9023067Abstract: A surgical system for small-pit closure in hollow organs is provided. The surgical system is provided with a surgical device for small-pit closure in hollow organs, with the surgical device including the following components: a suture-member cartridge in which a pair of parallel tubular members that accommodate respective suture members are feedably connected to the rear ends of a pair of arrow-shaped members that latch into tissue in a hollow organ; an auxiliary shooting unit having plungers respectively provided in a pair of cylinders open at both ends; a hollow-organ-insertable unit configured of a pair of flexible air tubes; and a gas shooter that sequentially discharges compressed air or high-pressure gas into the open-ended cylinders in response to operations of a trigger, for sequentially ejecting the arrow-shaped members and driving the same into tissue in the hollow organ on both sides of a small pit site.Type: GrantFiled: July 12, 2010Date of Patent: May 5, 2015Assignee: Educational Foundation Jichi Medical UniversityInventor: Takeshi Ohdaira
-
Patent number: 9023365Abstract: A recombinant transfer vector capable of expressing a foreign gene fused to a viral gene under the control of dual promoters and a recombinant baculovirus, and methods for production thereof, as well as pharmaceuticals comprising the recombinant baculovirus as an active ingredient.Type: GrantFiled: February 8, 2007Date of Patent: May 5, 2015Assignees: Educational Foundation Jichi Medical University, Otsuka Pharmaceutical Co., Ltd.Inventors: Shigeto Yoshida, Yoshio Ohba, Norimitsu Hariguchi, Masami Mizukoshi, Masanori Kawasaki, Makoto Matsumoto, Yoshihiro Goto
-
Patent number: 8640940Abstract: A system and method for use in NOTES is provided for reducing surgical invasiveness. An insertion body that is connected by an anvil assembly and joined to a thin wire guide or electric guide wire, is inserted via a natural orifice into a hollow organ so as to incise and remove a diseased or defective site from the hollow organ by using a pair of or front-end/rear-end linear cutters of a linear cutting/stapling device or linear stapler, after which the two cut ends of the tract are anastomosed and recovered by a circular anastomosis surgical stapler that is provided with the system.Type: GrantFiled: April 28, 2009Date of Patent: February 4, 2014Assignee: Educational Foundation Jichi Medical UniversityInventor: Takeshi Ohdaira
-
Publication number: 20130244259Abstract: [Problem] The present invention provides a novel pathological marker of angiitis which serves as an alternative to MPO-ANCAs. [Means for Solution]According to one embodiment of the present invention, a method for testing angiitis which includes a step of detecting an antibody specifically recognizing a moesin in a biological sample is provided. In addition, according to another embodiment of the present invention, a reagent for testing angiitis which contains a substance that detects an antibody specifically recognizing a moesin in a biological sample is provided.Type: ApplicationFiled: May 12, 2011Publication date: September 19, 2013Applicants: EDUCATIONAL FOUNDATION JICHI MEDICAL UNIVERSITY, NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITYInventors: Kazuo Suzuki, Toshinori Nakayama, Hiroshi Nakajima, Tomokazu Nagao, Wako Yumura
-
Publication number: 20130102006Abstract: Polynucleotides which are novel causative genes for cancer are elucidated, and a detection method of the polynucleotides or polypeptides encoded by the polynucleotides, and a kit and a primer set for detection are provided, based on the knowledge gained by the elucidation. In the detection method, a fusion gene comprising part of an SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 gene and part of a ROS1 gene, or a fusion protein encoded by the fusion gene is detected. The primer set or the detection kit comprises a sense primer designed based on a portion encoding SDC4, CD74, EZR, SLC34A2, LRIG3, or TPM3 and an antisense primer designed based on a portion encoding ROS1.Type: ApplicationFiled: June 22, 2011Publication date: April 25, 2013Applicants: Astellas Pharma Inc., Educational Foundation Jichi Medical University, Japanese Foundation For Cancer ResearchInventors: Kengo Takeuchi, Yuichi Ishikawa, Hiroyuki Mano, Manabu Soda, Eirin Sai
-
Publication number: 20130022637Abstract: The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients.Type: ApplicationFiled: September 14, 2012Publication date: January 24, 2013Applicants: OTSUKA PHARMACEUTICAL CO., LTD., EDUCATIONAL FOUNDATION JICHI MEDICAL UNIVERSITYInventors: Shigeto YOSHIDA, Masanori KAWASAKI, Makoto MATSUMOTO, Yoshio OHBA, Masahiro SAITO, Yoshihiro GOTO, Katsuya INAGAKI, Masami MIZUKOSHI, Norimitsu HARIGUCHI, Kuniko HIROTA
-
Patent number: 8309512Abstract: The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): (a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1; (b) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (a) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity; (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; and (d) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (c) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity, as an active component.Type: GrantFiled: August 22, 2011Date of Patent: November 13, 2012Assignees: Educational Foundation Jichi Medical University, Otsuka Pharmaceutical Co., LtdInventors: Shigeto Yoshida, Toshiki Sudo
-
Publication number: 20120004186Abstract: The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): (a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1; (b) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (a) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity; (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; and (d) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (c) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity, as an active component.Type: ApplicationFiled: August 22, 2011Publication date: January 5, 2012Applicants: OTSUKA PHARMACEUTICAL CO., LTD., EDUCATIONAL FOUNDATION JICHI MEDICAL UNIVERSITYInventors: Shigeto YOSHIDA, Toshiki SUDO
-
Patent number: 8034763Abstract: The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): (a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1; (b) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (a) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity; (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; and (d) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (c) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity, as an active component.Type: GrantFiled: November 2, 2006Date of Patent: October 11, 2011Assignees: Educational Foundation Jichi Medical University, Otsuka Pharmaceutical Co., Ltd.Inventors: Shigeto Yoshida, Toshiki Sudo
-
Publication number: 20100004164Abstract: The invention provides a pharmaceutical composition comprising at least one polypeptide of the following (a) to (d): (a) a polypeptide comprising the amino acid sequence of SEQ ID NO:1; (b) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (a) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity; (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:3; and (d) a polypeptide comprising an amino acid sequence comprising one or more amino acid deletions, insertions, substitutions or additions in the amino acid sequence of the above (c) and having a platelet aggregation inhibitory activity and/or a platelet adhesion inhibitory activity, as an active component.Type: ApplicationFiled: November 2, 2006Publication date: January 7, 2010Applicant: Educational Foundation Jichi Medical UniversityInventors: Shigeto Yoshida, Toshiki Sudo